Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	89.36	47.96	57.81	87.74	51.84
Short-Term Investments	284.52	205.24	186.8	299.52	284.01
Cash & Cash Equivalents	373.88	253.2	244.61	387.26	335.84
Cash Growth	47.66%	3.51%	-36.84%	15.31%	8.57%
Receivables	8.61	20.32	23.58	23.49	51.31
Other Current Assets	40.3	38.2	50.84	26.09	14.69
Total Current Assets	422.79	311.71	319.02	436.84	401.85
Property, Plant & Equipment	34.71	29.75	10.65	15.62	10.93
Long-Term Investments	0	29.29	108.42	32.63	65.01
Other Long-Term Assets	4.77	4.66	0.7	1.05	12.04
Total Long-Term Assets	39.48	63.7	119.77	49.3	87.98
Total Assets	462.28	375.41	438.79	486.13	489.83
Accounts Payable	4.1	6	9.54	5.74	6.69
Current Debt	5.28	2.89	4.2	4.26	0
Other Current Liabilities	53.42	20.94	22.43	14.16	15.92
Total Current Liabilities	62.79	29.83	36.17	24.16	22.61
Long-Term Debt	21.24	22.37	1.13	3.84	0
Other Long-Term Liabilities	161.52	1.88	2.06	2.56	4.73
Total Long-Term Liabilities	182.75	24.25	3.19	6.4	4.73
Total Liabilities	245.54	54.08	39.36	30.55	27.34
Total Debt	26.51	25.26	5.33	8.1	0
Debt Growth	4.95%	374.07%	-34.20%	-	-
Retained Earnings	-207	-73.18	48.58	127.57	163.74
Comprehensive Income	-1.17	-3.72	-0.38	0.84	0.15
Shareholders' Equity	216.74	321.33	399.43	455.58	462.49
Net Cash / Debt	347.37	227.94	239.28	379.16	335.84
Net Cash / Debt Growth	52.40%	-4.74%	-36.89%	12.90%	8.57%
Net Cash Per Share	16.57	11.06	11.86	19.01	16.02
Working Capital	360	281.89	282.85	412.68	379.24
Book Value Per Share	10.34	15.60	19.80	22.85	23.62

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).